Intravesical chemotherapy and immunotherapy are two localised treatment methods for bladder cancer. These therapies involve directly administering agents into the bladder through a catheter, targeting cancer cells while minimising systemic side effects. Intravesical therapy is typically used for non-muscle-invasive bladder cancer (NMIBC) to reduce recurrence and progression.
While intravesical immunotherapy and intravesical chemotherapy are both treatments administered directly into the bladder, they are not the same. Intravesical immunotherapy uses the body’s immune system to fight cancer, typically using agents to stimulate an immune response against bladder cancer cells. Intravesical chemotherapy, on the other hand, involves the direct application of anti-cancer drugs into the bladder to kill cancer cells. Both aim to treat bladder cancer locally, but their mechanisms of action differ significantly.
Immediate Aftercare: Patients are usually able to go home shortly after the procedure. They are advised to drink plenty of fluids to flush out the bladder.
Activity: Patients can typically resume normal activities immediately, but strenuous activities should be avoided for 24 to 48 hours.
Follow-Up: Regular cystoscopic evaluations are necessary to monitor the bladder for any signs of cancer recurrence. The frequency of follow-ups depends on the individual’s risk factors and response to treatment.
Effectiveness: Intravesical BCG is effective in approximately 70% of patients with NMIBC, significantly reducing the risk of recurrence and progression. Chemotherapy is also effective, though the response rates may vary.
Long-Term Management: For some patients, maintenance therapy is required. BCG maintenance therapy, for instance, can continue for several years to sustain its benefits.
Survival Rates: The prognosis for patients with NMIBC undergoing intravesical therapy is generally favourable, especially when the disease is detected early and treated promptly.
Patients should contact their healthcare provider if they experience any of the following:
Intravesical chemotherapy and immunotherapy represent cornerstone treatments for NMIBC, offering a targeted approach with the potential to preserve bladder function and improve long-term outcomes. Through careful management of side effects and consistent follow-ups, patients can achieve significant benefits from these therapies. Reach out to Assure Urology and Robotic Centre if you are seeking intravesical immunotherapy or chemotherapy as part of your bladder cancer treatment plan.
No issue is too small. Contact any of our friendly staff and we will get back to you as soon as possible.
Reach out to us for expert urological care.
For enquiries, leave a message and our friendly team will get in touch with you.
For urgent enquiries after office hours, call or WhatsApp us at (65) 9835 0668.
Monday – Friday: 9:00AM – 5:00PM
Saturday: 9:00AM – 12:30PM
Sunday & Public Holiday: CLOSED
Reach out to us for expert urological care.
For enquiries, leave a message and our friendly team will get in touch with you.
For urgent enquiries after office hours, call or WhatsApp us at (65) 8082 1366.
Monday – Friday: 9:00AM – 1:00PM | 2:00PM – 5:00PM
Weekends & Public Holidays: CLOSED
© 2023 All Rights Reserved | Assure Urology & Robotic Centre | Terms & Conditions